Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.26
HAE's Cash to Debt is ranked lower than
80% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. HAE: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
HAE' s 10-Year Cash to Debt Range
Min: 0.09  Med: 0.96 Max: 60.69
Current: 0.26
0.09
60.69
Equity to Asset 0.56
HAE's Equity to Asset is ranked lower than
56% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HAE: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
HAE' s 10-Year Equity to Asset Range
Min: 0.52  Med: 0.69 Max: 0.84
Current: 0.56
0.52
0.84
F-Score: 5
Z-Score: 3.18
M-Score: -2.90
WACC vs ROIC
6.64%
2.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.09
HAE's Operating margin (%) is ranked lower than
52% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.56 vs. HAE: 5.09 )
Ranked among companies with meaningful Operating margin (%) only.
HAE' s 10-Year Operating margin (%) Range
Min: 4.45  Med: 12.55 Max: 23.59
Current: 5.09
4.45
23.59
Net-margin (%) 2.25
HAE's Net-margin (%) is ranked lower than
53% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.77 vs. HAE: 2.25 )
Ranked among companies with meaningful Net-margin (%) only.
HAE' s 10-Year Net-margin (%) Range
Min: -8.68  Med: 9.12 Max: 16.46
Current: 2.25
-8.68
16.46
ROE (%) 2.48
HAE's ROE (%) is ranked lower than
57% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. HAE: 2.48 )
Ranked among companies with meaningful ROE (%) only.
HAE' s 10-Year ROE (%) Range
Min: -11.81  Med: 10.67 Max: 17.36
Current: 2.48
-11.81
17.36
ROA (%) 1.38
HAE's ROA (%) is ranked lower than
54% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. HAE: 1.38 )
Ranked among companies with meaningful ROA (%) only.
HAE' s 10-Year ROA (%) Range
Min: -7.51  Med: 7.84 Max: 13.64
Current: 1.38
-7.51
13.64
ROC (Joel Greenblatt) (%) 7.96
HAE's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. HAE: 7.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HAE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8.72  Med: 26.03 Max: 62.73
Current: 7.96
-8.72
62.73
Revenue Growth (3Y)(%) 7.40
HAE's Revenue Growth (3Y)(%) is ranked higher than
64% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. HAE: 7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HAE' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5  Med: 8.40 Max: 15
Current: 7.4
-1.5
15
EBITDA Growth (3Y)(%) -3.30
HAE's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. HAE: -3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HAE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.3  Med: 5.00 Max: 106.5
Current: -3.3
-9.3
106.5
EPS Growth (3Y)(%) -37.30
HAE's EPS Growth (3Y)(%) is ranked lower than
90% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. HAE: -37.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HAE' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.3  Med: 8.00 Max: 141
Current: -37.3
-37.3
141
» HAE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

HAE Guru Trades in Q3 2014

Ken Fisher 177,645 sh (unchged)
Paul Tudor Jones Sold Out
James Barrow 2,842,114 sh (-2.88%)
Joel Greenblatt 29,531 sh (-23.47%)
Jim Simons 36,700 sh (-82.91%)
» More
Q4 2014

HAE Guru Trades in Q4 2014

Jim Simons 100,400 sh (+173.57%)
Ken Fisher 194,245 sh (+9.34%)
Joel Greenblatt Sold Out
James Barrow 2,348,871 sh (-17.35%)
» More
Q1 2015

HAE Guru Trades in Q1 2015

Joel Greenblatt 7,510 sh (New)
Ken Fisher 194,245 sh (unchged)
James Barrow 2,345,971 sh (-0.12%)
Jim Simons 84,300 sh (-16.04%)
» More
Q2 2015

HAE Guru Trades in Q2 2015

Joel Greenblatt 35,271 sh (+369.65%)
James Barrow 2,336,063 sh (-0.42%)
Ken Fisher 189,520 sh (-2.43%)
Jim Simons 46,300 sh (-45.08%)
» More
» Details

Insider Trades

Latest Guru Trades with HAE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 94.49
HAE's P/E(ttm) is ranked lower than
91% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.70 vs. HAE: 94.49 )
Ranked among companies with meaningful P/E(ttm) only.
HAE' s 10-Year P/E(ttm) Range
Min: 17.15  Med: 26.29 Max: 138.58
Current: 94.49
17.15
138.58
Forward P/E 18.12
HAE's Forward P/E is ranked higher than
65% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.41 vs. HAE: 18.12 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 98.50
HAE's PE(NRI) is ranked lower than
92% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.80 vs. HAE: 98.50 )
Ranked among companies with meaningful PE(NRI) only.
HAE' s 10-Year PE(NRI) Range
Min: 17.01  Med: 26.26 Max: 139.88
Current: 98.5
17.01
139.88
P/B 2.31
HAE's P/B is ranked higher than
56% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. HAE: 2.31 )
Ranked among companies with meaningful P/B only.
HAE' s 10-Year P/B Range
Min: 1.94  Med: 2.63 Max: 3.43
Current: 2.31
1.94
3.43
P/S 2.09
HAE's P/S is ranked higher than
58% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. HAE: 2.09 )
Ranked among companies with meaningful P/S only.
HAE' s 10-Year P/S Range
Min: 1.74  Med: 2.46 Max: 3.59
Current: 2.09
1.74
3.59
PFCF 144.77
HAE's PFCF is ranked lower than
94% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.91 vs. HAE: 144.77 )
Ranked among companies with meaningful PFCF only.
HAE' s 10-Year PFCF Range
Min: 11.59  Med: 27.76 Max: 497.33
Current: 144.77
11.59
497.33
POCF 15.36
HAE's POCF is ranked higher than
58% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.50 vs. HAE: 15.36 )
Ranked among companies with meaningful POCF only.
HAE' s 10-Year POCF Range
Min: 9.59  Med: 15.06 Max: 25.59
Current: 15.36
9.59
25.59
EV-to-EBIT 47.14
HAE's EV-to-EBIT is ranked lower than
85% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.94 vs. HAE: 47.14 )
Ranked among companies with meaningful EV-to-EBIT only.
HAE' s 10-Year EV-to-EBIT Range
Min: 9.9  Med: 16.70 Max: 71.9
Current: 47.14
9.9
71.9
Shiller P/E 37.99
HAE's Shiller P/E is ranked lower than
66% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.01 vs. HAE: 37.99 )
Ranked among companies with meaningful Shiller P/E only.
HAE' s 10-Year Shiller P/E Range
Min: 21.66  Med: 31.08 Max: 45.09
Current: 37.99
21.66
45.09
Current Ratio 2.99
HAE's Current Ratio is ranked higher than
65% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. HAE: 2.99 )
Ranked among companies with meaningful Current Ratio only.
HAE' s 10-Year Current Ratio Range
Min: 2.17  Med: 3.34 Max: 4.92
Current: 2.99
2.17
4.92
Quick Ratio 1.75
HAE's Quick Ratio is ranked higher than
55% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. HAE: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
HAE' s 10-Year Quick Ratio Range
Min: 1.53  Med: 2.30 Max: 4.22
Current: 1.75
1.53
4.22
Days Inventory 163.82
HAE's Days Inventory is ranked lower than
70% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. HAE: 163.82 )
Ranked among companies with meaningful Days Inventory only.
HAE' s 10-Year Days Inventory Range
Min: 89.4  Med: 118.40 Max: 175.7
Current: 163.82
89.4
175.7
Days Sales Outstanding 56.46
HAE's Days Sales Outstanding is ranked higher than
59% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. HAE: 56.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
HAE' s 10-Year Days Sales Outstanding Range
Min: 58.47  Med: 74.89 Max: 86.97
Current: 56.46
58.47
86.97

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.62
HAE's Price/Tangible Book is ranked lower than
78% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. HAE: 8.62 )
Ranked among companies with meaningful Price/Tangible Book only.
HAE' s 10-Year Price/Tangible Book Range
Min: 1.69  Med: 3.35 Max: 13.78
Current: 8.62
1.69
13.78
Price/Projected FCF 1.66
HAE's Price/Projected FCF is ranked higher than
51% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. HAE: 1.66 )
Ranked among companies with meaningful Price/Projected FCF only.
HAE' s 10-Year Price/Projected FCF Range
Min: 1.09  Med: 1.52 Max: 2.56
Current: 1.66
1.09
2.56
Price/Median PS Value 0.84
HAE's Price/Median PS Value is ranked higher than
69% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. HAE: 0.84 )
Ranked among companies with meaningful Price/Median PS Value only.
HAE' s 10-Year Price/Median PS Value Range
Min: 0.54  Med: 0.94 Max: 1.39
Current: 0.84
0.54
1.39
Price/Graham Number 5.92
HAE's Price/Graham Number is ranked lower than
87% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. HAE: 5.92 )
Ranked among companies with meaningful Price/Graham Number only.
HAE' s 10-Year Price/Graham Number Range
Min: 1.12  Med: 1.91 Max: 7.85
Current: 5.92
1.12
7.85
Earnings Yield (Greenblatt) (%) 2.12
HAE's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. HAE: 2.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HAE' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.4  Med: 6.00 Max: 10.1
Current: 2.12
1.4
10.1
Forward Rate of Return (Yacktman) (%) -1.12
HAE's Forward Rate of Return (Yacktman) (%) is ranked lower than
79% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.01 vs. HAE: -1.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HAE' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -1.4  Med: 9.95 Max: 19.2
Current: -1.12
-1.4
19.2

Analyst Estimate

Mar16 Mar17 Mar18
Revenue(Mil) 947 1,004 1,072
EPS($) 2.00 2.30 2.84
EPS without NRI($) 2.00 2.30 2.84

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HAZ.Germany,
Haemonetics Corp is a Massachusetts corporation founded in 1971. It is a healthcare company that provides blood management solutions to its customers. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helps improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals. Its product categories include: Plasma, Blood Center, Hospital, and Software Solutions. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. The Company's competitors include Terumo BCT, Sorin Biomedica and Fresenius SE & Co. KGaA. The products it manufactures and markets are subject to regulation by the Center of Biologics Evaluation and Research and the Center of Devices and Radiological Health of the United States Food and Drug Administration, and other non-United States regulatory bodies.
» More Articles for HAE

Headlines

Articles On GuruFocus.com
DENTSPLY´s Growth Opportunities Dec 16 2014 
Meridian Contrarian Fund Second Quarter Commentary Sep 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders Jul 22 2014 
This Blood Management Company Can Be A Safe Investment Jul 13 2014 
Meridian Funds Comments on Haemonetics Aug 28 2013 
Meridian Funds' Second Quarter 2013 Commentary Aug 28 2013 
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT Jun 24 2013 
Allscripts-Misys Reports 5 Insider Buys the Day Before Barclays Conference Mar 13 2013 
Weekly Guru Bargains Highlights: HAE, DLTR, QCOR, MTX, AMD Jan 21 2013 

More From Other Websites
Haemonetics Introduces Award-Winning HaemoCloud™ - Embracing the Internet of Things to Connect the... Aug 11 2015
HAEMONETICS CORP Financials Aug 06 2015
10-Q for Haemonetics Corp. Aug 01 2015
HAEMONETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 30 2015
Haemonetics Q1 Earnings Beat Estimates, Revenues Miss - Analyst Blog Jul 28 2015
Haemonetics upgraded by Barrington Research Jul 28 2015
Edited Transcript of HAE earnings conference call or presentation 27-Jul-15 12:00pm GMT Jul 27 2015
Haemonetics Corp Earnings Call scheduled for 8:00 am ET today Jul 27 2015
Q1 2016 Haemonetics Corp Earnings Release - Before Market Open Jul 27 2015
Haemonetics reports 1Q loss Jul 27 2015
Haemonetics reports 1Q loss Jul 27 2015
HAEMONETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 27 2015
Haemonetics Reports 1st Quarter Fiscal 2016 Revenue of $213 Million and Adjusted EPS of $0.35,... Jul 27 2015
HAEMONETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jul 24 2015
New Strong Sell Stocks for July 20th - Tale of the Tape Jul 20 2015
Haemonetics Sets Date for First Quarter Fiscal Year 2016 Earnings Release: July 27, 2015 Jun 30 2015
/C O R R E C T I O N -- Haemonetics Corporation/ Jun 05 2015
Haemonetics to Present at The Goldman Sachs 36th Annual Global Healthcare Conference Jun 02 2015
Haemonetics to Present at the JMP Securities Life Sciences Conference May 29 2015
Haemonetics to Present at The East Coast IDEAS Investor Conference May 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK